Table 4.
Univariate and multivariate cox regression analyses for overall survival in cervical cancer patients in validation cohort.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Age | ||||
| ≤ 45 years vs. >45years | 0.62 (0.32–1.19) | 0.153 | – | – |
| Histological grade | 0.682 | |||
| G1 | Ref. | – | – | |
| G2 | 1.72 (0.39–7.51) | 0.473 | – | – |
| G3 | 1.90 (0.44–8.13) | 0.387 | – | – |
| Tumor size | ||||
| >4 vs. ≤4 | 2.12 (1.09–4.10) | 0.026* | 1.08 (0.51–2.31) | 0.841 |
| Tumor invasion depth | ||||
| >1/2 vs. ≤1/2 | 2.06 (1.07–3.96) | 0.030* | 1.89 (0.95–3.75) | 0.070 |
| Lymphovascular invasion | ||||
| Yes vs. No | 2.35 (1.23–4.48) | 0.010* | 2.16 (1.09–4.25) | 0.026* |
| 2018 FIGO stage | <0.001* | 0.008* | ||
| IA | Ref. | Ref. | ||
| IB | 4.27 (0.97–18.80) | 0.055 | 4.21 (0.93–19.20) | 0.063 |
| IIA | 12.10 (2.83–51.68) | 0.001* | 9.62 (2.00–46.23) | 0.005* |
| Radiotherapy | ||||
| Yes vs. No | 1.23 (0.61–2.49) | 0.567 | ||
| Chemoradiotherapy | ||||
| Yes vs. No | 1.38 (0.65–2.92) | 0.404 | ||
| SIRI | ||||
| >1.25 vs. ≤1.25 | 2.36 (1.23–4.52) | 0.009* | 1.97 (1.01–3.85) | 0.048* |
| NLR | ||||
| >2.8 vs. ≤2.8 | 2.24 (1.05–4.74) | 0.036* | 1.74 (0.88–3.42) | 0.110 |
| PLR | ||||
| >135 vs. ≤135 | 1.87 (0.98–3.56) | 0.059 | ||
| MLR | ||||
| >0.29 vs. ≤0.29 | 2.03 (1.02–4.04) | 0.044* | 1.79 (0.91–3.53) | 0.093 |
FIGO, International Federation of Gynecology and Obstetrics; SIRI, systemic inflammation response index; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; MLR, monocyte lymphocyte ratio; HR, hazard ratio; CI, confidence interval; Ref, reference.
*
Statistically significant (P < 0.05).